AI Support Integrated Into Routine Prenatal Ultrasound
BrightHeart has announced the availability of its B-Right AI Platform through GE HealthCare’s Voluson™ Solution Store. According to the company, the collaboration is designed to embed AI-based decision support directly into routine prenatal ultrasound exams, supporting earlier detection of congenital defects and more consistent scan quality.
The Voluson Solution Store, described as the first digital marketplace dedicated to Women’s Health ultrasound, is available in the U.S. and Europe. Through this platform, BrightHeart’s AI capabilities can be accessed within the existing Voluson ecosystem, without requiring separate systems or workflow changes.
Addressing Variability in Prenatal Screening
Prenatal ultrasound remains a central tool for detecting structural anomalies, which are identified in up to 6% of pregnancies. However, BrightHeart notes that more than 30% of congenital defects are still not detected before birth. Variability in image acquisition, interpretation, and resource availability—combined with ongoing sonographer shortages and care deserts in some regions—continues to challenge consistent prenatal screening.
By integrating AI-based guidance into Voluson ultrasound systems, the collaboration aims to provide clinicians with expert-level support throughout the full exam. The B-Right AI Platform offers assistance during image acquisition, interpretation, and review, with the goal of reducing diagnostic uncertainty and improving exam completeness across care settings.
Clinical Evidence and Workflow Integration
BrightHeart states that its AI platform is supported by clinical evidence, including two recent publications in The Green Journal. Developed in collaboration with fetal cardiology and maternal-fetal medicine (MFM) experts, the platform is positioned as a tool that goes beyond basic quality checks, providing structured, evidence-based insights during prenatal exams.
The cloud-based solution is designed to integrate into routine workflows, supporting OB/GYNs and MFMs without disrupting established clinical processes. According to the company, the platform has demonstrated benefits not only in screening performance, but also in workflow efficiency, including improved scan completeness, time savings, and increased clinician confidence.
Statements From the Companies
“Working closely with GE HealthCare allows us to deliver best-in-class AI tools exactly where clinicians need it within the workflows they already trust,” said Cécile Dupont, CEO of BrightHeart. “By combining our AI with Voluson ultrasound, we’re helping care teams perform more complete, efficient, and reproducible anatomy exams, reinforcing our shared commitment to elevate prenatal care.”
Gerald Seifriedsberger, General Manager, Women’s Health Ultrasound at GE HealthCare, added: “GE HealthCare is a proven leader in delivering clinically meaningful AI innovations to providers. Making BrightHeart’s B-Right AI Platform available through the Voluson Solution Store—the first digital marketplace for Women’s Health ultrasound—puts clinically validated AI directly into the hands of Voluson customers. It helps care teams perform more complete and consistent prenatal exams and supports significantly improved performance in congenital defect screening.”
Expanding Access to AI-Enabled Prenatal Care
BrightHeart’s platform is already in clinical use and is designed to support connected care at scale, from initial image acquisition to final review. By leveraging GE HealthCare’s established Voluson user base, the companies aim to broaden access to AI-supported prenatal ultrasound and support more consistent screening outcomes.
Source: BrightHeart
